Neuland Laboratories Limited (NEULANDLAB.BO)
INR 14649.65
(-0.98%)
INR 14649.65
(-0.98%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -214.05 Million INR | -125.78% |
| 2022 | 830.33 Million INR | -64.73% |
| 2021 | 2.35 Billion INR | 30.9% |
| 2020 | 1.79 Billion INR | -28.78% |
| 2019 | 2.52 Billion INR | 12.98% |
| 2018 | 2.23 Billion INR | -29.25% |
| 2017 | 3.15 Billion INR | 67.45% |
| 2016 | 1.88 Billion INR | 15.85% |
| 2015 | 1.62 Billion INR | -5.34% |
| 2014 | 1.72 Billion INR | 3.38% |
| 2013 | 1.66 Billion INR | -8.86% |
| 2012 | 1.82 Billion INR | -1.42% |
| 2011 | 1.85 Billion INR | -7.53% |
| 2010 | 2 Billion INR | -8.85% |
| 2009 | 2.19 Billion INR | 16.15% |
| 2008 | 1.89 Billion INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 875.75 Million INR | 509.12% |
| 2023 Q4 | -214.05 Million INR | -115.68% |
| 2023 Q1 | 454.15 Million INR | -45.3% |
| 2023 Q3 | 1.36 Billion INR | 667.61% |
| 2023 FY | -214.05 Million INR | -125.78% |
| 2023 Q2 | -240.56 Million INR | -152.97% |
| 2022 Q2 | 2.02 Billion INR | 2291.12% |
| 2022 FY | 830.33 Million INR | -64.73% |
| 2022 Q1 | 84.68 Million INR | -96.4% |
| 2022 Q4 | 830.33 Million INR | 260.0% |
| 2022 Q3 | 230.65 Million INR | -88.61% |
| 2021 Q2 | 2.11 Billion INR | 2276.95% |
| 2021 Q1 | 88.91 Million INR | -95.06% |
| 2021 Q3 | 366.5 Million INR | -82.66% |
| 2021 FY | 2.35 Billion INR | 30.9% |
| 2021 Q4 | 2.35 Billion INR | 542.4% |
| 2020 Q3 | 445.12 Million INR | -79.34% |
| 2020 Q2 | 2.15 Billion INR | 1051.73% |
| 2020 FY | 1.79 Billion INR | -28.78% |
| 2020 Q1 | 187.03 Million INR | -92.59% |
| 2020 Q4 | 1.79 Billion INR | 304.06% |
| 2019 Q4 | 2.52 Billion INR | 445.6% |
| 2019 FY | 2.52 Billion INR | 12.98% |
| 2019 Q3 | 462.84 Million INR | -76.49% |
| 2019 Q2 | 1.96 Billion INR | 1175.31% |
| 2019 Q1 | 154.37 Million INR | -93.09% |
| 2018 FY | 2.23 Billion INR | -29.25% |
| 2018 Q4 | 2.23 Billion INR | 0.0% |
| 2018 Q1 | 107.87 Million INR | 0.0% |
| 2017 FY | 3.15 Billion INR | 67.45% |
| 2016 Q3 | 1.92 Billion INR | 25.16% |
| 2016 Q1 | 97.14 Million INR | 0.0% |
| 2016 Q2 | 1.53 Billion INR | 1480.47% |
| 2016 FY | 1.88 Billion INR | 15.85% |
| 2016 Q4 | 1.88 Billion INR | -1.81% |
| 2015 FY | 1.62 Billion INR | -5.34% |
| 2014 FY | 1.72 Billion INR | 3.38% |
| 2013 FY | 1.66 Billion INR | -8.86% |
| 2012 FY | 1.82 Billion INR | -1.42% |
| 2011 FY | 1.85 Billion INR | -7.53% |
| 2010 FY | 2 Billion INR | -8.85% |
| 2009 FY | 2.19 Billion INR | 16.15% |
| 2008 FY | 1.89 Billion INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Ajanta Pharma Limited | -954.9 Million INR | 77.583% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 13.961% |
| Sigachi Industries Limited | 859.94 Million INR | 124.892% |
| Bal Pharma Limited | 1.26 Billion INR | 116.941% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 94.846% |
| Medico Remedies Limited | 78.67 Million INR | 372.072% |
| Lasa Supergenerics Limited | 205.79 Million INR | 204.013% |
| Venus Remedies Limited | -267.7 Million INR | 20.038% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 77.271% |
| Alpa Laboratories Limited | 35.36 Million INR | 705.316% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 103.476% |
| Shilpa Medicare Limited | 9.06 Billion INR | 102.36% |
| Aarti Drugs Limited | 5.54 Billion INR | 103.858% |
| Lupin Limited | 17.19 Billion INR | 101.245% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 105.796% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 105.472% |
| Windlas Biotech Limited | -273.04 Million INR | 21.602% |
| Suven Life Sciences Limited | -1.63 Billion INR | 86.889% |
| Eris Lifesciences Limited | 13.8 Billion INR | 101.55% |
| Valiant Laboratories Limited | -295.03 Million INR | 27.446% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 107.587% |
| Solara Active Pharma Sciences Limited | 10.02 Billion INR | 102.134% |
| Ipca Laboratories Limited | 11.41 Billion INR | 101.875% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 81.511% |
| Achyut Healthcare Limited | -3.74 Million INR | -5614.309% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 99.705% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 106.489% |
| RPG Life Sciences Limited | -364.7 Million INR | 41.306% |
| Mankind Pharma Limited | -9.9 Billion INR | 97.84% |
| Laurus Labs Limited | 24.38 Billion INR | 100.878% |
| Piramal Pharma Limited | 42.27 Billion INR | 100.506% |
| Syncom Formulations (India) Limited | 46.21 Million INR | 563.219% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 100.673% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 105.537% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 95.005% |
| Unichem Laboratories Limited | 931.91 Million INR | 122.97% |
| Sequent Scientific Limited | 4.17 Billion INR | 105.123% |
| Novartis India Limited | -5.89 Billion INR | 96.366% |
| Wanbury Limited | 1.1 Billion INR | 119.356% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | 247.651% |
| Wockhardt Limited | 18.27 Billion INR | 101.172% |
| Themis Medicare Limited | 764.96 Million INR | 127.983% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 84.599% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 100.791% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 92.47% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 101.658% |
| Divi's Laboratories Limited | -39.77 Billion INR | 99.462% |
| NATCO Pharma Limited | -5.81 Billion INR | 96.32% |
| Gufic Biosciences Limited | 3.19 Billion INR | 106.701% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 80.563% |
| Ind-Swift Limited | 9.5 Billion INR | 102.251% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 90.883% |
| FDC Limited | -57.75 Million INR | -270.65% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 111.074% |
| Granules India Limited | 9.28 Billion INR | 102.305% |
| Medicamen Biotech Limited | 160.31 Million INR | 233.523% |
| Alkem Laboratories Limited | -1.6 Billion INR | 86.7% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 95.729% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | -1060.458% |
| Brooks Laboratories Limited | 49.48 Million INR | 532.571% |
| Megasoft Limited | 1.28 Billion INR | 116.651% |
| ZIM Laboratories Limited | 983.6 Million INR | 121.763% |
| Strides Pharma Science Limited | 23.25 Billion INR | 100.92% |
| Morepen Laboratories Limited | -231.17 Million INR | 7.404% |
| Hikal Limited | 7.96 Billion INR | 102.687% |
| Indoco Remedies Limited | 6.47 Billion INR | 103.305% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 108.195% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | 278.324% |
| Mangalam Drugs & Organics Limited | 975.81 Million INR | 121.936% |
| Hester Biosciences Limited | 2.29 Billion INR | 109.344% |